

Supplementary References

1. Koskinen, M., Pöyhönen, L. & Seppänen, S. Thallium-201 washout in coronary artery disease using SPECT--a comparison with coronary angiography. *Eur J Nucl Med* **12**, 609-612, doi:10.1007/bf00284536 (1987).
2. Hecht, H. S. *et al.* Usefulness of tomographic thallium-201 imaging for detection of restenosis after percutaneous transluminal coronary angioplasty. *Am J Cardiol* **66**, 1314-1318, doi:10.1016/0002-9149(90)91160-8 (1990).
3. Chae, S. C., Heo, J., Iskandrian, A. S., Wasserleben, V. & Cave, V. Identification of extensive coronary artery disease in women by exercise single-photon emission computed tomographic (SPECT) thallium imaging. *J Am Coll Cardiol* **21**, 1305-1311, doi:10.1016/0735-1097(93)90301-g (1993).
4. Mairesse, G. H. *et al.* How accurate is dobutamine stress electrocardiography for detection of coronary artery disease? Comparison with two-dimensional echocardiography and technetium-99m methoxyl isobutyl isonitrile (mibi) perfusion scintigraphy. *J Am Coll Cardiol* **24**, 920-927, doi:10.1016/0735-1097(94)90850-8 (1994).
5. Kajinami, K., Seki, H., Takekoshi, N. & Mabuchi, H. Noninvasive prediction of coronary atherosclerosis by quantification of coronary artery calcification using electron beam computed tomography: comparison with electrocardiographic and thallium exercise stress test results. *J Am Coll Cardiol* **26**, 1209-1221, doi:10.1016/0735-1097(95)00314-2 (1995).
6. Nallamothu, N., Ghods, M., Heo, J. & Iskandrian, A. S. Comparison of thallium-201 single-photon emission computed tomography and electrocardiographic response during exercise in patients with normal rest electrocardiographic results. *J Am Coll Cardiol* **25**, 830-836, doi:10.1016/0735-1097(94)00471-2 (1995).
7. Hamasaki, S. *et al.* Increase in the delta ST/delta heart rate (HR) index: a new predictor of restenosis after successful percutaneous transluminal coronary angioplasty. *Am J Cardiol* **78**,

990-995, doi:10.1016/s0002-9149(96)00522-x (1996).

8. Khattar, R. S., Senior, R. & Lahiri, A. Assessment of myocardial perfusion and contractile function by inotropic stress Tc-99m sestamibi SPECT imaging and echocardiography for optimal detection of multivessel coronary artery disease. *Heart* **79**, 274-280, doi:10.1136/hrt.79.3.274 (1998).

9. Santana-Boado, C. *et al.* Diagnostic accuracy of technetium-99m-MIBI myocardial SPECT in women and men. *J Nucl Med* **39**, 751-755 (1998).

10. Michaelides, A. P. *et al.* Improved detection of coronary artery disease by exercise electrocardiography with the use of right precordial leads. *N Engl J Med* **340**, 340-345, doi:10.1056/nejm199902043400502 (1999).

11. Beygui, F. *et al.* Detection of coronary restenosis by exercise electrocardiography thallium-201 perfusion imaging and coronary angiography in asymptomatic patients after percutaneous transluminal coronary angioplasty. *Am J Cardiol* **86**, 35-40, doi:10.1016/s0002-9149(00)00825-0 (2000).

12. Gentile, R. *et al.* Diagnostic accuracy and prognostic implications of stress testing for coronary artery disease in the elderly. *Ital Heart J* **2**, 539-545 (2001).

13. Daou, D. *et al.* Identification of extensive coronary artery disease: incremental value of exercise TI-201 SPECT to clinical and stress test variables. *J Nucl Cardiol* **9**, 161-168, doi:10.1067/mnc.2002.119974 (2002).

14. Picano, E. *et al.* Prognostic importance of dipyridamole-echocardiography test in coronary artery disease. *Circulation* **80**, 450-457, doi:10.1161/01.cir.80.3.450 (1989).

15. Crouse, L. J., Harbrecht, J. J., Vacek, J. L., Rosamond, T. L. & Kramer, P. H. Exercise echocardiography as a screening test for coronary artery disease and correlation with coronary arteriography. *Am J Cardiol* **67**, 1213-1218, doi:10.1016/0002-9149(91)90929-f (1991).

16. Ferrara, N. *et al.* Dipyridamole echocardiography as a useful and safe test in the assessment of coronary artery disease in the elderly. *J Am Geriatr Soc* **39**, 993-999, doi:10.1111/j.1532-5415.1991.tb04046.x (1991).
17. Marcovitz, P. A. & Armstrong, W. F. Accuracy of dobutamine stress echocardiography in detecting coronary artery disease. *Am J Cardiol* **69**, 1269-1273, doi:10.1016/0002-9149(92)91219-t (1992).
18. Marwick, T. H., Nemecek, J. J., Pashkow, F. J., Stewart, W. J. & Salcedo, E. E. Accuracy and limitations of exercise echocardiography in a routine clinical setting. *J Am Coll Cardiol* **19**, 74-81, doi:10.1016/0735-1097(92)90054-q (1992).
19. Quiñones, M. A. *et al.* Exercise echocardiography versus 201Tl single-photon emission computed tomography in evaluation of coronary artery disease. Analysis of 292 patients. *Circulation* **85**, 1026-1031, doi:10.1161/01.cir.85.3.1026 (1992).
20. Hecht, H. S. *et al.* Digital supine bicycle stress echocardiography: a new technique for evaluating coronary artery disease. *J Am Coll Cardiol* **21**, 950-956, doi:10.1016/0735-1097(93)90352-2 (1993).
21. Hecht, H. S. *et al.* Supine bicycle stress echocardiography: peak exercise imaging is superior to postexercise imaging. *J Am Soc Echocardiogr* **6**, 265-271, doi:10.1016/s0894-7317(14)80062-x (1993).
22. Marwick, T. *et al.* Optimal use of dobutamine stress for the detection and evaluation of coronary artery disease: combination with echocardiography or scintigraphy, or both? *J Am Coll Cardiol* **22**, 159-167, doi:10.1016/0735-1097(93)90830-t (1993).
23. Picano, E. *et al.* Enhanced sensitivity for detection of coronary artery disease by addition of atropine to dipyridamole echocardiography. *Eur Heart J* **14**, 1216-1222, doi:10.1093/eurheartj/14.9.1216 (1993).
24. Takeuchi, M., Araki, M., Nakashima, Y. & Kuroiwa, A. Comparison of dobutamine

stress echocardiography and stress thallium-201 single-photon emission computed tomography for detecting coronary artery disease. *J Am Soc Echocardiogr* **6**, 593-602, doi:10.1016/s0894-7317(14)80177-6 (1993).

25. Beleslin, B. D. *et al.* Stress echocardiography in the detection of myocardial ischemia. Head-to-head comparison of exercise, dobutamine, and dipyridamole tests. *Circulation* **90**, 1168-1176, doi:10.1161/01.cir.90.3.1168 (1994).

26. Ostojic, M. *et al.* Dipyridamole-dobutamine echocardiography: a novel test for the detection of milder forms of coronary artery disease. *J Am Coll Cardiol* **23**, 1115-1122, doi:10.1016/0735-1097(94)90599-1 (1994).

27. Severi, S. *et al.* Diagnostic and prognostic value of dipyridamole echocardiography in patients with suspected coronary artery disease. Comparison with exercise electrocardiography. *Circulation* **89**, 1160-1173, doi:10.1161/01.cir.89.3.1160 (1994).

28. Geleijnse, M. L. *et al.* Optimal pharmacological stress testing for the diagnosis of coronary artery disease: a probabilistic approach. *Eur Heart J* **16 Suppl M**, 3-10, doi:10.1093/eurheartj/16.suppl_m.3 (1995).

29. Latham, A. P., Orsinelli, D. A. & Pearson, A. C. Recognition of the segmental tendency of false-positive dobutamine stress echocardiograms and its effects on test sensitivity and specificity. *Am Heart J* **129**, 1047-1050, doi:10.1016/0002-8703(95)90134-5 (1995).

30. Marwick, T. H. *et al.* Exercise echocardiography is an accurate and cost-efficient technique for detection of coronary artery disease in women. *J Am Coll Cardiol* **26**, 335-341, doi:10.1016/0735-1097(95)80004-z (1995).

31. Marwick, T. H. *et al.* Influence of left ventricular hypertrophy on detection of coronary artery disease using exercise echocardiography. *J Am Coll Cardiol* **26**, 1180-1186, doi:10.1016/0735-1097(96)81472-0 (1995).

32. Roger, V. L. *et al.* Stress echocardiography. Part I. Exercise echocardiography:

techniques, implementation, clinical applications, and correlations. *Mayo Clin Proc* **70**, 5-15, doi:10.1016/s0025-6196(11)64659-4 (1995).

33. Anthopoulos, L. P. *et al.* Stress echocardiography in elderly patients with coronary artery disease: applicability, safety and prognostic value of dobutamine and adenosine echocardiography in elderly patients. *J Am Coll Cardiol* **28**, 52-59, doi:10.1016/0735-1097(96)00127-1 (1996).

34. Bartunek, J. *et al.* Dobutamine-induced wall motion abnormalities: correlations with myocardial fractional flow reserve and quantitative coronary angiography. *J Am Coll Cardiol* **27**, 1429-1436, doi:10.1016/0735-1097(96)00022-8 (1996).

35. Elhendy, A. *et al.* Accuracy of dobutamine stress echocardiography for the diagnosis of coronary artery stenosis in patients with myocardial infarction: the impact of extent and severity of left ventricular dysfunction. *Heart* **76**, 123-128, doi:10.1136/hrt.76.2.123 (1996).

36. Hoffmann, R. *et al.* Analysis of interinstitutional observer agreement in interpretation of dobutamine stress echocardiograms. *J Am Coll Cardiol* **27**, 330-336, doi:10.1016/0735-1097(95)00483-1 (1996).

37. Pingitore, A. *et al.* The atropine factor in pharmacologic stress echocardiography. Echo Persantine (EPIC) and Echo Dobutamine International Cooperative (EDIC) Study Groups. *J Am Coll Cardiol* **27**, 1164-1170, doi:10.1016/0735-1097(95)00586-2 (1996).

38. San Román, J. A. *et al.* Dipyridamole and dobutamine-atropine stress echocardiography in the diagnosis of coronary artery disease. Comparison with exercise stress test, analysis of agreement, and impact of antianginal treatment. *Chest* **110**, 1248-1254, doi:10.1378/chest.110.5.1248 (1996).

39. Hennessy, T. G. *et al.* Dobutamine stress echocardiography in the detection of coronary artery disease: importance of the pretest likelihood of disease. *Am Heart J* **134**, 685-692, doi:10.1016/s0002-8703(97)70052-8 (1997).

40. Ho, Y. L. *et al.* Assessment of the functional significance of coronary artery stenosis by dobutamine-atropine stress echocardiography. *Cardiology* **88**, 386-392, doi:10.1159/000177364 (1997).
41. Roger, V. L. *et al.* Sex and test verification bias. Impact on the diagnostic value of exercise echocardiography. *Circulation* **95**, 405-410, doi:10.1161/01.cir.95.2.405 (1997).
42. Elhendy, A. *et al.* Optimal criteria for the diagnosis of coronary artery disease by dobutamine stress echocardiography. *Am J Cardiol* **82**, 1339-1344, doi:10.1016/s0002-9149(98)00638-9 (1998).
43. Elhendy, A. *et al.* Safety and feasibility of dobutamine-atropine stress echocardiography for the diagnosis of coronary artery disease in diabetic patients unable to perform an exercise stress test. *Diabetes Care* **21**, 1797-1802, doi:10.2337/diacare.21.11.1797 (1998).
44. Hennessy, T. G. *et al.* Detection of coronary artery disease using dobutamine stress echocardiography in patients with an abnormal resting electrocardiograph. *Int J Cardiol* **64**, 293-298, doi:10.1016/s0167-5273(98)00077-1 (1998).
45. Miyazono, Y. *et al.* Usefulness of adenosine triphosphate-atropine stress echocardiography for detecting coronary artery stenosis. *Am J Cardiol* **82**, 290-294, doi:10.1016/s0002-9149(98)00345-2 (1998).
46. San Román, J. A. *et al.* Selection of the optimal stress test for the diagnosis of coronary artery disease. *Heart* **80**, 370-376, doi:10.1136/hrt.80.4.370 (1998).
47. Fragasso, G. *et al.* Comparison of stress/rest myocardial perfusion tomography, dipyridamole and dobutamine stress echocardiography for the detection of coronary disease in hypertensive patients with chest pain and positive exercise test. *J Am Coll Cardiol* **34**, 441-447, doi:10.1016/s0735-1097(99)00231-4 (1999).
48. Hoffmann, R., Lethen, H., Kühl, H., Lepper, W. & Hanrath, P. Extent and severity of test positivity during dobutamine stress echocardiography. Influence on the predictive value for

coronary artery disease. *Eur Heart J* **20**, 1485-1492, doi:10.1053/euhj.1999.1628 (1999).

49. Nagel, E. *et al.* [Influence of image quality on the diagnostic accuracy of dobutamine stress magnetic resonance imaging in comparison with dobutamine stress echocardiography for the noninvasive detection of myocardial ischemia]. *Z Kardiol* **88**, 622-630, doi:10.1007/s003920050337 (1999).

50. Parodi, G. *et al.* High dose dipyridamole myocardial imaging: simultaneous sestamibi scintigraphy and two-dimensional echocardiography in the detection and evaluation of coronary artery disease. Italian Group of Nuclear Cardiology. *Coron Artery Dis* **10**, 177-184, doi:10.1097/00019501-199905000-00007 (1999).

51. Smart, S. C., Knickelbine, T., Malik, F. & Sagar, K. B. Dobutamine-atropine stress echocardiography for the detection of coronary artery disease in patients with left ventricular hypertrophy. Importance of chamber size and systolic wall stress. *Circulation* **101**, 258-263, doi:10.1161/01.cir.101.3.258 (2000).

52. Dolan, M. S. *et al.* Effect of intravenous contrast for left ventricular opacification and border definition on sensitivity and specificity of dobutamine stress echocardiography compared with coronary angiography in technically difficult patients. *Am Heart J* **142**, 908-915, doi:10.1067/mhj.2001.117608 (2001).

53. Pasierski, T. *et al.* Advantages of exercise echocardiography in comparison to dobutamine echocardiography in the diagnosis of coronary artery disease in hypertensive subjects. *J Hum Hypertens* **15**, 805-809, doi:10.1038/sj.jhh.1001265 (2001).

54. Nedeljkovic, I. *et al.* Comparison of exercise, dobutamine-atropine and dipyridamole-atropine stress echocardiography in detecting coronary artery disease. *Cardiovasc Ultrasound* **4**, 22, doi:10.1186/1476-7120-4-22 (2006).

55. Hanekom, L., Cho, G. Y., Leano, R., Jeffriess, L. & Marwick, T. H. Comparison of two-dimensional speckle and tissue Doppler strain measurement during dobutamine stress

echocardiography: an angiographic correlation. *Eur Heart J* **28**, 1765-1772, doi:10.1093/eurheartj/ehm188 (2007).

56. Porter, T. R. *et al.* Rapid detection of coronary artery stenoses with real-time perfusion echocardiography during regadenoson stress. *Circ Cardiovasc Imaging* **4**, 628-635, doi:10.1161/circimaging.111.966341 (2011).

57. Celutkiene, J. *et al.* Quantitative approach using multiple single parameters versus visual assessment in dobutamine stress echocardiography. *Cardiovasc Ultrasound* **10**, 31, doi:10.1186/1476-7120-10-31 (2012).

58. Peteiro, J. *et al.* Head-to-head comparison of peak supine bicycle exercise echocardiography and treadmill exercise echocardiography at peak and at post-exercise for the detection of coronary artery disease. *J Am Soc Echocardiogr* **25**, 319-326, doi:10.1016/j.echo.2011.11.002 (2012).

59. Mahmarian, J. J. *et al.* Quantitative exercise thallium-201 single photon emission computed tomography for the enhanced diagnosis of ischemic heart disease. *J Am Coll Cardiol* **15**, 318-329, doi:10.1016/s0735-1097(10)80055-5 (1990).

60. Christian, T. F., Miller, T. D., Bailey, K. R. & Gibbons, R. J. Noninvasive identification of severe coronary artery disease using exercise tomographic thallium-201 imaging. *Am J Cardiol* **70**, 14-20, doi:10.1016/0002-9149(92)91382-e (1992).

61. Mohiuddin, S. M., Ravage, C. K., Esterbrooks, D. J., Lucas, B. D., Jr. & Hilleman, D. E. The comparative safety and diagnostic accuracy of adenosine myocardial perfusion imaging in women versus men. *Pharmacotherapy* **16**, 646-651 (1996).

62. Amanullah, A. M., Berman, D. S., Kiat, H. & Friedman, J. D. Usefulness of hemodynamic changes during adenosine infusion in predicting the diagnostic accuracy of adenosine technetium-99m sestamibi single-photon emission computed tomography (SPECT). *Am J Cardiol* **79**, 1319-1322, doi:10.1016/s0002-9149(97)00132-x (1997).

63. Miller, D. D., Younis, L. T., Chaitman, B. R. & Stratmann, H. Diagnostic accuracy of dipyridamole technetium 99m-labeled sestamibi myocardial tomography for detection of coronary artery disease. *J Nucl Cardiol* **4**, 18-24, doi:10.1016/s1071-3581(97)90045-3 (1997).
64. Gallowitsch, H. J. *et al.* Attenuation-corrected thallium-201 single-photon emission tomography using a gadolinium-153 moving line source: clinical value and the impact of attenuation correction on the extent and severity of perfusion abnormalities. *Eur J Nucl Med* **25**, 220-228, doi:10.1007/s002590050220 (1998).
65. Psirropoulos, D. *et al.* Detection of myocardial ischemia in the elderly versus the young by stress thallium-201 scintigraphy and its relation to important coronary artery disease. *Heart Vessels* **16**, 131-136, doi:10.1007/s003800200009 (2002).
66. Shirai, N. *et al.* Incremental value of assessment of regional wall motion for detection of multivessel coronary artery disease in exercise (201)Tl gated myocardial perfusion imaging. *J Nucl Med* **43**, 443-450 (2002).
67. Doyle, M. *et al.* The impact of myocardial flow reserve on the detection of coronary artery disease by perfusion imaging methods: an NHLBI WISE study. *J Cardiovasc Magn Reson* **5**, 475-485, doi:10.1081/jcmr-120022263 (2003).
68. Groutars, R. G. *et al.* The accuracy of 1-day dual-isotope myocardial SPECT in a population with high prevalence of coronary artery disease. *Int J Cardiovasc Imaging* **19**, 229-238, doi:10.1023/a:1023637804898 (2003).
69. Shelley, S. *et al.* Adenosine myocardial SPECT--its efficacy and safety and correlation with coronary angiogram. *J Assoc Physicians India* **51**, 557-560 (2003).
70. Dondi, M. *et al.* Myocardial SPECT: what do we gain from attenuation correction (and when)? *Q J Nucl Med Mol Imaging* **48**, 181-187 (2004).
71. Hambye, A. S., Vervae, A. M. & Dobbeleir, A. A. Head-to-head comparison of uncorrected and scatter corrected, summed and end diastolic myocardial perfusion SPECT in

coronary artery disease. *Nucl Med Commun* **25**, 347-353, doi:10.1097/00006231-200404000-00006 (2004).

72. González, P. *et al.* 201Tl myocardial SPECT detects significant coronary artery disease between 50% and 75% angiogram stenosis. *Rev Esp Med Nucl* **24**, 305-311, doi:10.1157/13079281 (2005).

73. Johansen, A. *et al.* Diagnostic accuracy of myocardial perfusion imaging in a study population without post-test referral bias. *J Nucl Cardiol* **12**, 530-537, doi:10.1016/j.nuclcard.2005.04.012 (2005).

74. Thompson, R. C. *et al.* Value of attenuation correction on ECG-gated SPECT myocardial perfusion imaging related to body mass index. *J Nucl Cardiol* **12**, 195-202, doi:10.1016/j.nuclcard.2004.12.298 (2005).

75. Berman, D. S. *et al.* Diagnostic accuracy of gated Tc-99m sestamibi stress myocardial perfusion SPECT with combined supine and prone acquisitions to detect coronary artery disease in obese and nonobese patients. *J Nucl Cardiol* **13**, 191-201, doi:10.1007/bf02971243 (2006).

76. Hung, G. U., Lee, K. W., Chen, C. P., Yang, K. T. & Lin, W. Y. Worsening of left ventricular ejection fraction induced by dipyridamole on Tl-201 gated myocardial perfusion imaging predicts significant coronary artery disease. *J Nucl Cardiol* **13**, 225-232, doi:10.1007/bf02971247 (2006).

77. Jeetley, P. *et al.* Myocardial contrast echocardiography for the detection of coronary artery stenosis: a prospective multicenter study in comparison with single-photon emission computed tomography. *J Am Coll Cardiol* **47**, 141-145, doi:10.1016/j.jacc.2005.08.054 (2006).

78. Slomka, P. J. *et al.* Simplified normal limits and automated quantitative assessment for attenuation-corrected myocardial perfusion SPECT. *J Nucl Cardiol* **13**, 642-651,

doi:10.1016/j.nuclcard.2006.06.131 (2006).

79. Sharples, L. *et al.* Cost-effectiveness of functional cardiac testing in the diagnosis and management of coronary artery disease: a randomised controlled trial. The CECaT trial. *Health Technol Assess* **11**, iii-iv, ix-115, doi:10.3310/hta11490 (2007).

80. Bokhari, S., Shahzad, A. & Bergmann, S. R. Superiority of exercise myocardial perfusion imaging compared with the exercise ECG in the diagnosis of coronary artery disease. *Coron Artery Dis* **19**, 399-404, doi:10.1097/MCA.0b013e3283021ab4 (2008).

81. Lipiec, P. *et al.* Accelerated stress real-time myocardial contrast echocardiography for the detection of coronary artery disease: comparison with ^{99m}Tc single photon emission computed tomography. *J Am Soc Echocardiogr* **21**, 941-947, doi:10.1016/j.echo.2008.02.004 (2008).

82. Tadehara, F. *et al.* Feasibility of a rapid protocol of 1-day single-isotope rest/adenosine stress Tc-99m sestamibi ECG-gated myocardial perfusion imaging. *J Nucl Cardiol* **15**, 35-41, doi:10.1016/j.nuclcard.2007.10.005 (2008).

83. Wolak, A. *et al.* Quantitative diagnostic performance of myocardial perfusion SPECT with attenuation correction in women. *J Nucl Med* **49**, 915-922, doi:10.2967/jnumed.107.049387 (2008).

84. Hida, S. *et al.* Diagnostic value of left ventricular function after adenosine triphosphate loading and at rest in the detection of multi-vessel coronary artery disease using myocardial perfusion imaging. *J Nucl Cardiol* **16**, 20-27, doi:10.1007/s12350-008-9003-7 (2009).

85. Wu, M. C., Chin, K. C., Lin, K. H. & Chiu, N. T. Diagnostic efficacy of a low-dose 32-projection SPECT ^{99m}Tc-sestamibi myocardial perfusion imaging protocol in routine practice. *Nucl Med Commun* **30**, 140-147, doi:10.1097/MNM.0b013e328319e65f (2009).

86. Yoon, A. J., Melduni, R. M., Duncan, S. A., Ostfeld, R. J. & Travin, M. I. The effect of beta-blockers on the diagnostic accuracy of vasodilator pharmacologic SPECT myocardial

- perfusion imaging. *J Nucl Cardiol* **16**, 358-367, doi:10.1007/s12350-009-9066-0 (2009).
87. Greenwood, J. P. *et al.* Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. *Lancet* **379**, 453-460, doi:10.1016/s0140-6736(11)61335-4 (2012).
88. Schwitter, J. *et al.* MR-IMPACT II: Magnetic Resonance Imaging for Myocardial Perfusion Assessment in Coronary artery disease Trial: perfusion-cardiac magnetic resonance vs. single-photon emission computed tomography for the detection of coronary artery disease: a comparative multicentre, multivendor trial. *Eur Heart J* **34**, 775-781, doi:10.1093/eurheartj/ehs022 (2013).
89. Yıldırım Poyraz, N. *et al.* Predictors and Diagnostic Significance of the Adenosine Related Side Effects on Myocardial Perfusion SPECT/CT Imaging. *Mol Imaging Radionucl Ther* **23**, 89-95, doi:10.4274/mirt.85057 (2014).
90. Neglia, D. *et al.* Detection of significant coronary artery disease by noninvasive anatomical and functional imaging. *Circ Cardiovasc Imaging* **8**, doi:10.1161/circimaging.114.002179 (2015).
91. Go, R. T. *et al.* A prospective comparison of rubidium-82 PET and thallium-201 SPECT myocardial perfusion imaging utilizing a single dipyridamole stress in the diagnosis of coronary artery disease. *J Nucl Med* **31**, 1899-1905 (1990).
92. Bateman, T. M. *et al.* Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT. *J Nucl Cardiol* **13**, 24-33, doi:10.1016/j.nuclcard.2005.12.004 (2006).
93. Kajander, S. A. *et al.* Clinical value of absolute quantification of myocardial perfusion with (15)O-water in coronary artery disease. *Circ Cardiovasc Imaging* **4**, 678-684, doi:10.1161/circimaging.110.960732 (2011).
94. Ishida, N. *et al.* Noninfarcted myocardium: correlation between dynamic first-pass

contrast-enhanced myocardial MR imaging and quantitative coronary angiography. *Radiology* **229**, 209-216, doi:10.1148/radiol.2291021118 (2003).

95. Takase, B. *et al.* Whole-heart dipyridamole stress first-pass myocardial perfusion MRI for the detection of coronary artery disease. *Jpn Heart J* **45**, 475-486, doi:10.1536/jhj.45.475 (2004).

96. Pilz, G. *et al.* Clinical implication of adenosine-stress cardiac magnetic resonance imaging as potential gatekeeper prior to invasive examination in patients with AHA/ACC class II indication for coronary angiography. *Clin Res Cardiol* **95**, 531-538, doi:10.1007/s00392-006-0422-7 (2006).

97. Merkle, N. *et al.* Assessment of myocardial perfusion for detection of coronary artery stenoses by steady-state, free-precession magnetic resonance first-pass imaging. *Heart* **93**, 1381-1385, doi:10.1136/hrt.2006.104232 (2007).

98. Bernhardt, P. *et al.* Combined assessment of myocardial perfusion and late gadolinium enhancement in patients after percutaneous coronary intervention or bypass grafts: a multicenter study of an integrated cardiovascular magnetic resonance protocol. *JACC Cardiovasc Imaging* **2**, 1292-1300, doi:10.1016/j.jcmg.2009.05.011 (2009).

99. Motwani, M. *et al.* High-resolution versus standard-resolution cardiovascular MR myocardial perfusion imaging for the detection of coronary artery disease. *Circ Cardiovasc Imaging* **5**, 306-313, doi:10.1161/circimaging.111.971796 (2012).

100. Chen, M. Y. *et al.* Concordance and diagnostic accuracy of vasodilator stress cardiac MRI and 320-detector row coronary CTA. *Int J Cardiovasc Imaging* **30**, 109-119, doi:10.1007/s10554-013-0300-0 (2014).

101. Groothuis, J. G. *et al.* Combined non-invasive functional and anatomical diagnostic work-up in clinical practice: the magnetic resonance and computed tomography in suspected coronary artery disease (MARCC) study. *Eur Heart J* **34**, 1990-1998,

doi:10.1093/eurheartj/eh077 (2013).

102. Meijboom, W. B. *et al.* 64-Slice CT coronary angiography in patients with non-ST elevation acute coronary syndrome. *Heart* **93**, 1386-1392, doi:10.1136/hrt.2006.112771 (2007).

103. Meijboom, W. B. *et al.* Comparison of diagnostic accuracy of 64-slice computed tomography coronary angiography in women versus men with angina pectoris. *Am J Cardiol* **100**, 1532-1537, doi:10.1016/j.amjcard.2007.06.061 (2007).

104. Shabestari, A. A. *et al.* Diagnostic performance of 64-channel multislice computed tomography in assessment of significant coronary artery disease in symptomatic subjects. *Am J Cardiol* **99**, 1656-1661, doi:10.1016/j.amjcard.2007.01.040 (2007).

105. Meijboom, W. B. *et al.* Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study. *J Am Coll Cardiol* **52**, 2135-2144, doi:10.1016/j.jacc.2008.08.058 (2008).

106. Budoff, M. J. *et al.* Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography) trial. *J Am Coll Cardiol* **52**, 1724-1732, doi:10.1016/j.jacc.2008.07.031 (2008).

107. Gueret, P. *et al.* Diagnostic performance of computed tomography coronary angiography (from the Prospective National Multicenter Multivendor EVASCAN Study). *Am J Cardiol* **111**, 471-478, doi:10.1016/j.amjcard.2012.10.029 (2013).

108. De Bruyne, B., Bartunek, J., Sys, S. U. & Heyndrickx, G. R. Relation between myocardial fractional flow reserve calculated from coronary pressure measurements and exercise-induced myocardial ischemia. *Circulation* **92**, 39-46, doi:10.1161/01.cir.92.1.39

(1995).

109. Pijls, N. H. *et al.* Fractional flow reserve. A useful index to evaluate the influence of an epicardial coronary stenosis on myocardial blood flow. *Circulation* **92**, 3183-3193, doi:10.1161/01.cir.92.11.3183 (1995).

110. Pijls, N. H. *et al.* Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. *N Engl J Med* **334**, 1703-1708, doi:10.1056/nejm199606273342604 (1996).

111. Jiménez-Navarro, M. *et al.* Measurement of fractional flow reserve to assess moderately severe coronary lesions: correlation with dobutamine stress echocardiography. *J Interv Cardiol* **14**, 499-504, doi:10.1111/j.1540-8183.2001.tb00365.x (2001).

112. Rieber, J. *et al.* Comparison of pressure measurement, dobutamine contrast stress echocardiography and SPECT for the evaluation of intermediate coronary stenoses. The COMPRESS trial. *Int J Cardiovasc Intervent* **6**, 142-147, doi:10.1080/14628840410030504 (2004).

113. Jung, P. H. *et al.* Effect of contrast application on interpretability and diagnostic value of dobutamine stress echocardiography in patients with intermediate coronary lesions: comparison with myocardial fractional flow reserve. *Eur Heart J* **29**, 2536-2543, doi:10.1093/eurheartj/ehn204 (2008).

114. Pattanshetty, D. J., Bhat, P. K., Gandhi, S., Pillai, D. P. & Aneja, A. Comparing stress testing and fractional flow reserve to evaluate presence, location and extent of ischemia in coronary artery disease. *Indian Heart J* **67**, 50-55, doi:10.1016/j.ihj.2015.02.010 (2015).

115. Wu, J. *et al.* Comparison of Fractional Flow Reserve Assessment With Demand Stress Myocardial Contrast Echocardiography in Angiographically Intermediate Coronary Stenoses. *Circ Cardiovasc Imaging* **9**, doi:10.1161/circimaging.116.004129 (2016).

116. Gurunathan, S. *et al.* Diagnostic Concordance and Clinical Outcomes in Patients

Undergoing Fractional Flow Reserve and Stress Echocardiography for the Assessment of Coronary Stenosis of Intermediate Severity. *J Am Soc Echocardiogr* **31**, 180-186, doi:10.1016/j.echo.2017.10.012 (2018).

117. Panoulas, V. F. *et al.* Association between fractional flow reserve, instantaneous wave-free ratio and dobutamine stress echocardiography in patients with stable coronary artery disease. *EuroIntervention* **13**, 1959-1966, doi:10.4244/eij-d-17-00594 (2018).

118. Abe, M., Tomiyama, H., Yoshida, H. & Doba, N. Diastolic fractional flow reserve to assess the functional severity of moderate coronary artery stenoses: comparison with fractional flow reserve and coronary flow velocity reserve. *Circulation* **102**, 2365-2370, doi:10.1161/01.cir.102.19.2365 (2000).

119. Caymaz, O. *et al.* Correlation of myocardial fractional flow reserve with thallium-201 SPECT imaging in intermediate-severity coronary artery lesions. *J Invasive Cardiol* **12**, 345-350 (2000).

120. Chamuleau, S. A. *et al.* Fractional flow reserve, absolute and relative coronary blood flow velocity reserve in relation to the results of technetium-99m sestamibi single-photon emission computed tomography in patients with two-vessel coronary artery disease. *J Am Coll Cardiol* **37**, 1316-1322, doi:10.1016/s0735-1097(01)01173-1 (2001).

121. De Bruyne, B. *et al.* Fractional flow reserve in patients with prior myocardial infarction. *Circulation* **104**, 157-162, doi:10.1161/01.cir.104.2.157 (2001).

122. Meuwissen, M. *et al.* Hyperemic stenosis resistance index for evaluation of functional coronary lesion severity. *Circulation* **106**, 441-446, doi:10.1161/01.cir.0000023041.26199.29 (2002).

123. Yanagisawa, H. *et al.* Correlation between thallium-201 myocardial perfusion defects and the functional severity of coronary artery stenosis as assessed by pressure-derived myocardial fractional flow reserve. *Circ J* **66**, 1105-1109, doi:10.1253/circj.66.1105 (2002).

124. Usui, Y. *et al.* Reliability of pressure-derived myocardial fractional flow reserve in assessing coronary artery stenosis in patients with previous myocardial infarction. *Am J Cardiol* **92**, 699-702, doi:10.1016/s0002-9149(03)00829-4 (2003).
125. Hacker, M. *et al.* Comparison of Tc-99m sestamibi SPECT with fractional flow reserve in patients with intermediate coronary artery stenoses. *J Nucl Cardiol* **12**, 645-654, doi:10.1016/j.nuclcard.2005.07.006 (2005).
126. Samady, H. *et al.* Fractional flow reserve of infarct-related arteries identifies reversible defects on noninvasive myocardial perfusion imaging early after myocardial infarction. *J Am Coll Cardiol* **47**, 2187-2193, doi:10.1016/j.jacc.2006.01.065 (2006).
127. Ragosta, M. *et al.* Comparison between angiography and fractional flow reserve versus single-photon emission computed tomographic myocardial perfusion imaging for determining lesion significance in patients with multivessel coronary disease. *Am J Cardiol* **99**, 896-902, doi:10.1016/j.amjcard.2006.11.035 (2007).
128. Förster, S. *et al.* Tc-99m sestamibi single photon emission computed tomography for guiding percutaneous coronary intervention in patients with multivessel disease: a comparison with quantitative coronary angiography and fractional flow reserve. *Int J Cardiovasc Imaging* **26**, 203-213, doi:10.1007/s10554-009-9510-x (2010).
129. Melikian, N. *et al.* Fractional flow reserve and myocardial perfusion imaging in patients with angiographic multivessel coronary artery disease. *JACC Cardiovasc Interv* **3**, 307-314, doi:10.1016/j.jcin.2009.12.010 (2010).
130. Jakljević, T. *et al.* Detection of myocardial ischemia in diabetic patients: the limitations of myocardial perfusion imaging. *Coll Antropol* **36**, 821-826 (2012).
131. Mouden, M. *et al.* Myocardial perfusion imaging with a cadmium zinc telluride-based gamma camera versus invasive fractional flow reserve. *Eur J Nucl Med Mol Imaging* **41**, 956-962, doi:10.1007/s00259-013-2630-5 (2014).

132. Sahiner, I. *et al.* Quantitative evaluation improves specificity of myocardial perfusion SPECT in the assessment of functionally significant intermediate coronary artery stenoses: a comparative study with fractional flow reserve measurements. *Ann Nucl Med* **27**, 132-139, doi:10.1007/s12149-012-0666-4 (2013).
133. Schaap, J. *et al.* Incremental diagnostic accuracy of hybrid SPECT/CT coronary angiography in a population with an intermediate to high pre-test likelihood of coronary artery disease. *Eur Heart J Cardiovasc Imaging* **14**, 642-649, doi:10.1093/ehjci/jes303 (2013).
134. van de Hoef, T. P. *et al.* Head-to-head comparison of basal stenosis resistance index, instantaneous wave-free ratio, and fractional flow reserve: diagnostic accuracy for stenosis-specific myocardial ischaemia. *EuroIntervention* **11**, 914-925, doi:10.4244/eijy14m08_17 (2015).
135. Danad, I. *et al.* Comparison of Coronary CT Angiography, SPECT, PET, and Hybrid Imaging for Diagnosis of Ischemic Heart Disease Determined by Fractional Flow Reserve. *JAMA Cardiol* **2**, 1100-1107, doi:10.1001/jamacardio.2017.2471 (2017).
136. Han, S. *et al.* Feasibility of dynamic stress (201)Tl/rest (99m)Tc-tetrofosmin single photon emission computed tomography for quantification of myocardial perfusion reserve in patients with stable coronary artery disease. *Eur J Nucl Med Mol Imaging* **45**, 2173-2180, doi:10.1007/s00259-018-4057-5 (2018).
137. Costa, M. A. *et al.* Quantitative magnetic resonance perfusion imaging detects anatomic and physiologic coronary artery disease as measured by coronary angiography and fractional flow reserve. *J Am Coll Cardiol* **50**, 514-522, doi:10.1016/j.jacc.2007.04.053 (2007).
138. Kühl, H. P. *et al.* Comparison of magnetic resonance perfusion imaging versus invasive fractional flow reserve for assessment of the hemodynamic significance of epicardial coronary artery stenosis. *Am J Cardiol* **99**, 1090-1095, doi:10.1016/j.amjcard.2006.11.061 (2007).

139. Watkins, S. *et al.* Validation of magnetic resonance myocardial perfusion imaging with fractional flow reserve for the detection of significant coronary heart disease. *Circulation* **120**, 2207-2213, doi:10.1161/circulationaha.109.872358 (2009).
140. Kirschbaum, S. W. *et al.* Comparison of adenosine magnetic resonance perfusion imaging with invasive coronary flow reserve and fractional flow reserve in patients with suspected coronary artery disease. *Int J Cardiol* **147**, 184-186, doi:10.1016/j.ijcard.2010.12.038 (2011).
141. Lockie, T. *et al.* High-resolution magnetic resonance myocardial perfusion imaging at 3.0-Tesla to detect hemodynamically significant coronary stenoses as determined by fractional flow reserve. *J Am Coll Cardiol* **57**, 70-75, doi:10.1016/j.jacc.2010.09.019 (2011).
142. Bernhardt, P., Walcher, T., Rottbauer, W. & Wöhrle, J. Quantification of myocardial perfusion reserve at 1.5 and 3.0 Tesla: a comparison to fractional flow reserve. *Int J Cardiovasc Imaging* **28**, 2049-2056, doi:10.1007/s10554-012-0037-1 (2012).
143. Huber, A. *et al.* Magnetic resonance perfusion of the myocardium: semiquantitative and quantitative evaluation in comparison with coronary angiography and fractional flow reserve. *Invest Radiol* **47**, 332-338, doi:10.1097/RLI.0b013e31824f54cb (2012).
144. Jogiya, R. *et al.* Validation of dynamic 3-dimensional whole heart magnetic resonance myocardial perfusion imaging against fractional flow reserve for the detection of significant coronary artery disease. *J Am Coll Cardiol* **60**, 756-765, doi:10.1016/j.jacc.2012.02.075 (2012).
145. Manka, R. *et al.* Whole-heart dynamic three-dimensional magnetic resonance perfusion imaging for the detection of coronary artery disease defined by fractional flow reserve: determination of volumetric myocardial ischaemic burden and coronary lesion location. *Eur Heart J* **33**, 2016-2024, doi:10.1093/eurheartj/ehs170 (2012).
146. Walcher, T. *et al.* Myocardial perfusion reserve assessed by T2-prepared steady-state

free precession blood oxygen level-dependent magnetic resonance imaging in comparison to fractional flow reserve. *Circ Cardiovasc Imaging* **5**, 580-586, doi:10.1161/circimaging.111.971507 (2012).

147. Bettencourt, N. *et al.* Cardiac magnetic resonance myocardial perfusion imaging for detection of functionally significant obstructive coronary artery disease: a prospective study. *Int J Cardiol* **168**, 765-773, doi:10.1016/j.ijcard.2012.09.231 (2013).

148. Chiribiri, A. *et al.* Assessment of coronary artery stenosis severity and location: quantitative analysis of transmural perfusion gradients by high-resolution MRI versus FFR. *JACC Cardiovasc Imaging* **6**, 600-609, doi:10.1016/j.jcmg.2012.09.019 (2013).

149. Pereira, E. *et al.* Incremental value of adenosine stress cardiac magnetic resonance in coronary artery disease detection. *Int J Cardiol* **168**, 4160-4167, doi:10.1016/j.ijcard.2013.07.114 (2013).

150. Ebersberger, U. *et al.* Magnetic resonance myocardial perfusion imaging at 3.0 Tesla for the identification of myocardial ischaemia: comparison with coronary catheter angiography and fractional flow reserve measurements. *Eur Heart J Cardiovasc Imaging* **14**, 1174-1180, doi:10.1093/ehjci/jet074 (2013).

151. Manka, R. *et al.* Multicenter evaluation of dynamic three-dimensional magnetic resonance myocardial perfusion imaging for the detection of coronary artery disease defined by fractional flow reserve. *Circ Cardiovasc Imaging* **8**, doi:10.1161/circimaging.114.003061 (2015).

152. Danad, I. *et al.* Hybrid imaging using quantitative H₂¹⁵O PET and CT-based coronary angiography for the detection of coronary artery disease. *J Nucl Med* **54**, 55-63, doi:10.2967/jnumed.112.104687 (2013).

153. Danad, I. *et al.* Impact of anatomical and functional severity of coronary atherosclerotic plaques on the transmural perfusion gradient: a [15O]H₂O PET study. *Eur Heart J* **35**, 2094-

2105, doi:10.1093/eurheartj/ehu170 (2014).

154. Joutsiniemi, E. *et al.* Absolute flow or myocardial flow reserve for the detection of significant coronary artery disease? *Eur Heart J Cardiovasc Imaging* **15**, 659-665, doi:10.1093/ehjci/jet274 (2014).

155. Ko, B. S. *et al.* Combined CT coronary angiography and stress myocardial perfusion imaging for hemodynamically significant stenoses in patients with suspected coronary artery disease: a comparison with fractional flow reserve. *JACC Cardiovasc Imaging* **5**, 1097-1111, doi:10.1016/j.jcmg.2012.09.004 (2012).

156. Ko, B. S. *et al.* Computed tomography stress myocardial perfusion imaging in patients considered for revascularization: a comparison with fractional flow reserve. *Eur Heart J* **33**, 67-77, doi:10.1093/eurheartj/ehr268 (2012).

157. Bettencourt, N. *et al.* Direct comparison of cardiac magnetic resonance and multidetector computed tomography stress-rest perfusion imaging for detection of coronary artery disease. *J Am Coll Cardiol* **61**, 1099-1107, doi:10.1016/j.jacc.2012.12.020 (2013).

158. Choo, K. S. *et al.* Adenosine-stress low-dose single-scan CT myocardial perfusion imaging using a 128-slice dual-source CT: a comparison with fractional flow reserve. *Acta Radiol* **54**, 389-395, doi:10.1177/0284185113475440 (2013).

159. Greif, M. *et al.* CT stress perfusion imaging for detection of haemodynamically relevant coronary stenosis as defined by FFR. *Heart* **99**, 1004-1011, doi:10.1136/heartjnl-2013-303794 (2013).

160. Huber, A. M. *et al.* Myocardium: dynamic versus single-shot CT perfusion imaging. *Radiology* **269**, 378-386, doi:10.1148/radiol.13121441 (2013).

161. Rossi, A. *et al.* Diagnostic performance of hyperaemic myocardial blood flow index obtained by dynamic computed tomography: does it predict functionally significant coronary lesions? *Eur Heart J Cardiovasc Imaging* **15**, 85-94, doi:10.1093/ehjci/jet133 (2014).

162. Yang DH, Kim YH, Roh JH, Kang JW, Ahn JM, Kweon J, Lee JB, Choi SH, Shin ES, Park DW, Kang SJ, Lee SW, Lee CW, Park SW, Park SJ, Lim TH. Diagnostic performance of on-site CT-derived fractional flow reserve versus CT perfusion. *Eur Heart J Cardiovasc Imaging*. 2017 Apr 1;18(4):432-440.
163. Ihdahid AR, Sakaguchi T, Linde JJ, Sørgaard MH, Kofoed KF, Fujisawa Y, Hislop-Jambrich J, Nerlekar N, Cameron JD, Munnur RK, Crosset M, Wong DTL, Seneviratne SK, Ko BS. Performance of computed tomography-derived fractional flow reserve using reduced-order modelling and static computed tomography stress myocardial perfusion imaging for detection of haemodynamically significant coronary stenosis. *Eur Heart J Cardiovasc Imaging*. 2018 Nov 1;19(11):1234-1243.
164. Sen, S. *et al.* Development and validation of a new adenosine-independent index of stenosis severity from coronary wave-intensity analysis: results of the ADVISE (ADenosine Vasodilator Independent Stenosis Evaluation) study. *J Am Coll Cardiol* **59**, 1392-1402, doi:10.1016/j.jacc.2011.11.003 (2012).
165. Petraco, R. *et al.* Classification performance of instantaneous wave-free ratio (iFR) and fractional flow reserve in a clinical population of intermediate coronary stenoses: results of the ADVISE registry. *EuroIntervention* **9**, 91-101, doi:10.4244/eijv9i1a14 (2013).
166. Berry, C. *et al.* VERIFY (VERification of Instantaneous Wave-Free Ratio and Fractional Flow Reserve for the Assessment of Coronary Artery Stenosis Severity in Everyday Practice): a multicenter study in consecutive patients. *J Am Coll Cardiol* **61**, 1421-1427, doi:10.1016/j.jacc.2012.09.065 (2013).
167. Park, J. J. *et al.* Clinical validation of the resting pressure parameters in the assessment of functionally significant coronary stenosis; results of an independent, blinded comparison with fractional flow reserve. *Int J Cardiol* **168**, 4070-4075, doi:10.1016/j.ijcard.2013.07.030 (2013).

168. Jeremias, A. *et al.* Multicenter core laboratory comparison of the instantaneous wave-free ratio and resting Pd/Pa with fractional flow reserve: the RESOLVE study. *J Am Coll Cardiol* **63**, 1253-1261, doi:10.1016/j.jacc.2013.09.060 (2014).
169. Petraco, R. *et al.* Baseline instantaneous wave-free ratio as a pressure-only estimation of underlying coronary flow reserve: results of the JUSTIFY-CFR Study (Joined Coronary Pressure and Flow Analysis to Determine Diagnostic Characteristics of Basal and Hyperemic Indices of Functional Lesion Severity-Coronary Flow Reserve). *Circ Cardiovasc Interv* **7**, 492-502, doi:10.1161/circinterventions.113.000926 (2014).
170. Petraco, R. *et al.* Real-time use of instantaneous wave-free ratio: results of the ADVISE in-practice: an international, multicenter evaluation of instantaneous wave-free ratio in clinical practice. *Am Heart J* **168**, 739-748, doi:10.1016/j.ahj.2014.06.022 (2014).
171. Escaned, J. *et al.* Prospective Assessment of the Diagnostic Accuracy of Instantaneous Wave-Free Ratio to Assess Coronary Stenosis Relevance: Results of ADVISE II International, Multicenter Study (ADenosine Vasodilator Independent Stenosis Evaluation II). *JACC Cardiovasc Interv* **8**, 824-833, doi:10.1016/j.jcin.2015.01.029 (2015).
172. Fede, A. *et al.* iFR-FFR comparison in daily practice: a single-center, prospective, online assessment. *J Cardiovasc Med (Hagerstown)* **16**, 625-631, doi:10.2459/jcm.0000000000000272 (2015).
173. Härle, T., Bojara, W., Meyer, S. & Elsässer, A. Comparison of instantaneous wave-free ratio (iFR) and fractional flow reserve (FFR)--first real world experience. *Int J Cardiol* **199**, 1-7, doi:10.1016/j.ijcard.2015.07.003 (2015).
174. Indolfi, C. *et al.* The instantaneous wave-free ratio (iFR) for evaluation of non-culprit lesions in patients with acute coronary syndrome and multivessel disease. *Int J Cardiol* **178**, 46-54, doi:10.1016/j.ijcard.2014.03.210 (2015).
175. Hennigan, B. *et al.* Discordance Between Resting and Hyperemic Indices of Coronary

Stenosis Severity: The VERIFY 2 Study (A Comparative Study of Resting Coronary Pressure Gradient, Instantaneous Wave-Free Ratio and Fractional Flow Reserve in an Unselected Population Referred for Invasive Angiography). *Circ Cardiovasc Interv* **9**, doi:10.1161/circinterventions.116.004016 (2016).

176. Kanaji, Y. *et al.* Efficacy of pressure parameters obtained during contrast medium-induced submaximal hyperemia in the functional assessment of intermediate coronary stenosis in comparison with instantaneous wave-free ratio. *Int J Cardiol* **208**, 128-136, doi:10.1016/j.ijcard.2016.01.205 (2016).

177. Cook, C. M. *et al.* Fractional Flow Reserve/Instantaneous Wave-Free Ratio Discordance in Angiographically Intermediate Coronary Stenoses: An Analysis Using Doppler-Derived Coronary Flow Measurements. *JACC Cardiovasc Interv* **10**, 2514-2524, doi:10.1016/j.jcin.2017.09.021 (2017).

178. Ding, W. Y., Nair, S. & Appleby, C. Diagnostic accuracy of instantaneous wave free-ratio in clinical practice. *J Interv Cardiol* **30**, 564-569, doi:10.1111/joic.12422 (2017).

179. Lee, J. M. *et al.* Discrepancy between fractional flow reserve and instantaneous wave-free ratio: Clinical and angiographic characteristics. *Int J Cardiol* **245**, 63-68, doi:10.1016/j.ijcard.2017.07.099 (2017).

180. Meimoun, P. *et al.* Assessment of left anterior descending artery stenosis of intermediate severity by fractional flow reserve, instantaneous wave-free ratio, and non-invasive coronary flow reserve. *Int J Cardiovasc Imaging* **33**, 999-1007, doi:10.1007/s10554-016-1000-3 (2017).

181. Scarsini, R. *et al.* Coronary physiology in patients with severe aortic stenosis: Comparison between fractional flow reserve and instantaneous wave-free ratio. *Int J Cardiol* **243**, 40-46, doi:10.1016/j.ijcard.2017.05.117 (2017).

182. Shiode, N. *et al.* A Comparison between the Instantaneous Wave-free Ratio and Resting

Distal Coronary Artery Pressure/Aortic Pressure and the Fractional Flow Reserve: The Diagnostic Accuracy Can Be Improved by the Use of both Indices. *Intern Med* **56**, 749-753, doi:10.2169/internalmedicine.56.7857 (2017).

183. Emori, H. *et al.* Quantitative flow ratio and instantaneous wave-free ratio for the assessment of the functional severity of intermediate coronary artery stenosis. *Coron Artery Dis* **29**, 611-617, doi:10.1097/mca.0000000000000650 (2018).

184. Nobre Menezes, M. *et al.* Comparative analysis of fractional flow reserve and instantaneous wave-free ratio: Results of a five-year registry. *Rev Port Cardiol (Engl Ed)* **37**, 511-520, doi:10.1016/j.repc.2017.11.011 (2018).

185. Pisters, R. *et al.* Instantaneous wave-free ratio and fractional flow reserve in clinical practice. *Neth Heart J* **26**, 385-392, doi:10.1007/s12471-018-1125-1 (2018).

186. Spagnoli, V. *et al.* Simplifying the assessment of coronary artery stenosis by enhancing instantaneous wave free ratio. *Cardiovasc Diagn Ther* **8**, 156-163, doi:10.21037/cdt.2017.12.04 (2018).

187. Lee, J. M. *et al.* Clinical Outcome of Lesions With Discordant Results Among Different Invasive Physiologic Indices - Resting Distal Coronary to Aortic Pressure Ratio, Resting Full-Cycle Ratio, Diastolic Pressure Ratio, Instantaneous Wave-Free Ratio, and Fractional Flow Reserve. *Circ J* **83**, 2210-2221, doi:10.1253/circj.CJ-19-0230 (2019).

188. Mehta, O. H. *et al.* Comparison of diagnostic performance between quantitative flow ratio, non-hyperemic pressure indices and fractional flow reserve. *Cardiovasc Diagn Ther* **10**, 442-452, doi:10.21037/cdt-20-179 (2020).

189. Onishi, K. *et al.* Determinants and prognostic implications of instantaneous wave-free ratio in patients with mild to intermediate coronary stenosis: Comparison with those of fractional flow reserve. *PLoS One* **15**, e0237275, doi:10.1371/journal.pone.0237275 (2020).

190. Tu S, Westra J, Yang J, von Birgelen C, Ferrara A, Pellicano M, Nef H, Tebaldi M,

Murasato Y, Lansky A, Barbato E, van der Heijden LC, Reiber JHC, Holm NR, Wijns W; FAVOR Pilot Trial Study Group. Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary Angiography: The International Multicenter FAVOR Pilot Study. *JACC Cardiovasc Interv.* 2016 Oct 10;9(19):2024-2035.

191. Yazaki K, Otsuka M, Kataoka S, Kahata M, Kumagai A, Inoue K, Koganei H, Enta K, Ishii Y. Applicability of 3-Dimensional Quantitative Coronary Angiography-Derived Computed Fractional Flow Reserve for Intermediate Coronary Stenosis. *Circ J.* 2017 Jun 23;81(7):988-992.

192. Xu B, Tu S, Qiao S, Qu X, Chen Y, Yang J, Guo L, Sun Z, Li Z, Tian F, Fang W, Chen J, Li W, Guan C, Holm NR, Wijns W, Hu S. Diagnostic Accuracy of Angiography-Based Quantitative Flow Ratio Measurements for Online Assessment of Coronary Stenosis. *J Am Coll Cardiol.* 2017 Dec 26;70(25):3077-3087. doi: 10.1016/j.jacc.2017.10.035.

193. Emori H, Kubo T, Kameyama T, Ino Y, Matsuo Y, Kitabata H, Terada K, Katayama Y, Aoki H, Taruya A, Shimamura K, Ota S, Tanaka A, Hozumi T, Akasaka T. Diagnostic Accuracy of Quantitative Flow Ratio for Assessing Myocardial Ischemia in Prior Myocardial Infarction. *Circ J.* 2018 Feb 23;82(3):807-814.

194. Westra J, Tu S, Winther S, Nissen L, Vestergaard MB, Andersen BK, Holck EN, Fox Maule C, Johansen JK, Andreasen LN, Simonsen JK, Zhang Y, Kristensen SD, Maeng M, Kaltoft A, Terkelsen CJ, Krusell LR, Jakobsen L, Reiber JHC, Lassen JF, Bøttcher M, Bøtker HE, Christiansen EH, Holm NR. Evaluation of Coronary Artery Stenosis by Quantitative Flow Ratio During Invasive Coronary Angiography: The WIFI II Study (Wire-Free Functional Imaging II). *Circ Cardiovasc Imaging.* 2018 Mar;11(3):e007107.

195. Westra J, Andersen BK, Campo G, Matsuo H, Koltowski L, Eftekhari A, Liu T, Di Serafino L, Di Girolamo D, Escaned J, Nef H, Naber C, Barbierato M, Tu S, Neghabat O, Madsen M, Tebaldi M, Tanigaki T, Kochman J, Somi S, Esposito G, Mercone G, Mejia-

Renteria H, Ronco F, Bøtker HE, Wijns W, Christiansen EH, Holm NR. Diagnostic Performance of In-Procedure Angiography-Derived Quantitative Flow Reserve Compared to Pressure-Derived Fractional Flow Reserve: The FAVOR II Europe-Japan Study. *J Am Heart Assoc.* 2018 Jul 6;7(14):e009603.

196. Kołtowski Ł, Zaleska M, Maksym J, Tomaniak M, Soliński M, Puchta D, Holm NR, Opolski G, Kochman J. Quantitative flow ratio derived from diagnostic coronary angiography in assessment of patients with intermediate coronary stenosis: a wire-free fractional flow reserve study. *Clin Res Cardiol.* 2018 Sep;107(9):858-867.

197. Ties D, van Dijk R, Pundziute G, Lipsic E, Vonck TE, van den Heuvel AFM, Vliegenthart R, Oudkerk M, van der Harst P. Computational quantitative flow ratio to assess functional severity of coronary artery stenosis. *Int J Cardiol.* 2018 Nov 15;271:36-41.

198. Zhang Y, Zhang S, Westra J, Ding D, Zhao Q, Yang J, Sun Z, Huang J, Pu J, Xu B, Tu S. Automatic coronary blood flow computation: validation in quantitative flow ratio from coronary angiography. *Int J Cardiovasc Imaging.* 2019 Apr;35(4):587-595.

199. Stähli BE, Erbay A, Steiner J, Klotsche J, Mochmann HC, Skurk C, Lauten A, Landmesser U, Leistner DM. Comparison of resting distal to aortic coronary pressure with angiography-based quantitative flow ratio. *Int J Cardiol.* 2019 Mar 15;279:12-17.

200. Smit JM, El Mahdiui M, van Rosendaal AR, Jukema JW, Koning G, Reiber JHC, Bax JJ, Scholte AJ. Comparison of Diagnostic Performance of Quantitative Flow Ratio in Patients With Versus Without Diabetes Mellitus. *Am J Cardiol.* 2019 May 15;123(10):1722-1728.

201. Hwang D, Choi KH, Lee JM, Mejía-Rentería H, Kim J, Park J, Rhee TM, Jeon KH, Lee HJ, Kim HK, Park TK, Yang JH, Song YB, Shin ES, Nam CW, Kwak JJ, Doh JH, Hahn JY, Choi JH, Choi SH, Escaned J, Koo BK, Gwon HC. Diagnostic Agreement of Quantitative Flow Ratio With Fractional Flow Reserve and Instantaneous Wave-Free Ratio. *J Am Heart Assoc.* 2019 Apr 16;8(8):e011605.

202. Tanigaki T, Emori H, Kawase Y, Kubo T, Omori H, Shiono Y, Sobue Y, Shimamura K, Hirata T, Matsuo Y, Ota H, Kitabata H, Okubo M, Ino Y, Matsuo H, Akasaka T. QFR Versus FFR Derived From Computed Tomography for Functional Assessment of Coronary Artery Stenosis. *JACC Cardiovasc Interv.* 2019 Oct 28;12(20):2050-2059.
203. Gutiérrez-Chico JL, Chen Y, Yu W, Ding D, Huang J, Huang P, Jing J, Chu M, Wu P, Tian F, Xu B, Tu S. Diagnostic accuracy and reproducibility of optical flow ratio for functional evaluation of coronary stenosis in a prospective series. *Cardiol J.* 2020;27(4):350-361.
204. Lauri FM, Macaya F, Mejía-Rentería H, Goto S, Yeoh J, Nakayama M, Quirós A, Lontou C, Pareek N, Fernández-Ortíz A, Macaya C, MacCarthy P, Escaned J; Collaborators. Angiography-derived functional assessment of non-culprit coronary stenoses in primary percutaneous coronary intervention. *EuroIntervention.* 2020 Apr 3;15(18):e1594-e1601.
205. Mejía-Rentería H, Nombela-Franco L, Paradis JM, Lunardi M, Lee JM, Amat-Santos IJ, Veiga Fernandez G, Kalra A, Bansal EJ, de la Torre Hernandez JM, Rodés-Cabau J, Ribichini FL, Escaned J; Collaborators. Angiography-based quantitative flow ratio versus fractional flow reserve in patients with coronary artery disease and severe aortic stenosis. *EuroIntervention.* 2020 Jul 17;16(4):e285-e292.
206. Kirigaya H, Okada K, Hibi K, Maejima N, Iwahashi N, Matsuzawa Y, Akiyama E, Minamimoto Y, Kosuge M, Ebina T, Tamura K, Kimura K. Diagnostic performance and limitation of quantitative flow ratio for functional assessment of intermediate coronary stenosis. *J Cardiol.* 2021 May;77(5):492-499.
207. Koo BK, Erglis A, Doh JH, Daniels DV, Jegere S, Kim HS, Dunning A, DeFrance T, Lansky A, Leipsic J, Min JK. Diagnosis of ischemia-causing coronary stenoses by noninvasive fractional flow reserve computed from coronary computed tomographic angiograms. Results from the prospective multicenter DISCOVER-FLOW (Diagnosis of

Ischemia-Causing Stenoses Obtained Via Noninvasive Fractional Flow Reserve) study. *J Am Coll Cardiol*. 2011 Nov 1;58(19):1989-97.

208. Min JK, Leipsic J, Pencina MJ, Berman DS, Koo BK, van Mieghem C, Erglis A, Lin FY, Dunning AM, Apruzzese P, Budoff MJ, Cole JH, Jaffer FA, Leon MB, Malpeso J, Mancini GB, Park SJ, Schwartz RS, Shaw LJ, Mauri L. Diagnostic accuracy of fractional flow reserve from anatomic CT angiography. *JAMA*. 2012 Sep 26;308(12):1237-45.

209. Nørgaard BL, Leipsic J, Gaur S, Seneviratne S, Ko BS, Ito H, Jensen JM, Mauri L, De Bruyne B, Bezerra H, Osawa K, Marwan M, Naber C, Erglis A, Park SJ, Christiansen EH, Kaltoft A, Lassen JF, Bøtker HE, Achenbach S; NXT Trial Study Group. Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: the NXT trial (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps). *J Am Coll Cardiol*. 2014 Apr 1;63(12):1145-1155.

210. Kruk M, Wardziak Ł, Demkow M, Pleban W, Pręgowski J, Dzielińska Z, Witulski M, Witkowski A, Rużyło W, Kępka C. Workstation-Based Calculation of CTA-Based FFR for Intermediate Stenosis. *JACC Cardiovasc Imaging*. 2016 Jun;9(6):690-9.

211. Ko BS, Cameron JD, Munnur RK, Wong DTL, Fujisawa Y, Sakaguchi T, Hirohata K, Hislop-Jambrich J, Fujimoto S, Takamura K, Crossett M, Leung M, Kuganesan A, Malaiapan Y, Nasis A, Troupis J, Meredith IT, Seneviratne SK. Noninvasive CT-Derived FFR Based on Structural and Fluid Analysis: A Comparison With Invasive FFR for Detection of Functionally Significant Stenosis. *JACC Cardiovasc Imaging*. 2017 Jun;10(6):663-673.

212. Driessen RS, Danad I, Stuijzand WJ, Raijmakers PG, Schumacher SP, van Diemen PA, Leipsic JA, Knuuti J, Underwood SR, van de Ven PM, van Rossum AC, Taylor CA, Knaapen P. Comparison of Coronary Computed Tomography Angiography, Fractional Flow Reserve, and Perfusion Imaging for Ischemia Diagnosis. *J Am Coll Cardiol*. 2019 Jan 22;73(2):161-

173.

213. Ko BS, Linde JJ, Ihsdayhid AR, Norgaard BL, Kofoed KF, Sørgaard M, Adams D, Crossett M, Cameron JD, Seneviratne SK. Non-invasive CT-derived fractional flow reserve and static rest and stress CT myocardial perfusion imaging for detection of haemodynamically significant coronary stenosis. *Int J Cardiovasc Imaging*. 2019 Nov;35(11):2103-2112.

214. Fujimoto S, Kawasaki T, Kumamaru KK, Kawaguchi Y, Dohi T, Okonogi T, Ri K, Yamada S, Takamura K, Kato E, Kato Y, Hiki M, Okazaki S, Aoki S, Mitsouras D, Rybicki FJ, Daida H. Diagnostic performance of on-site computed CT-fractional flow reserve based on fluid structure interactions: comparison with invasive fractional flow reserve and instantaneous wave-free ratio. *Eur Heart J Cardiovasc Imaging*. 2019 Mar 1;20(3):343-352.

215. Hartigan, P. M., Giacomini, J. C., Folland, E. D. & Parisi, A. F. Two- to three-year follow-up of patients with single-vessel coronary artery disease randomized to PTCA or medical therapy (results of a VA cooperative study). Veterans Affairs Cooperative Studies Program ACME Investigators. Angioplasty Compared to Medicine. *Am J Cardiol* **82**, 1445-1450, doi:10.1016/s0002-9149(98)00685-7 (1998).

216. Parisi, A. F., Folland, E. D. & Hartigan, P. A Comparison of Angioplasty with Medical Therapy in the Treatment of Single-Vessel Coronary Artery Disease. *New England Journal of Medicine* **326**, 10-16, doi:10.1056/nejm199201023260102 (1992).

217. Folland, E. D., Hartigan, P. M. & Parisi, A. F. Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris: outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs Cooperative randomized trial. Veterans Affairs ACME InvestigatorS. *J Am Coll Cardiol* **29**, 1505-1511, doi:10.1016/s0735-1097(97)00097-1 (1997).

218. Pitt, B. *et al.* Aggressive lipid-lowering therapy compared with angioplasty in stable

coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. *N Engl J Med* **341**, 70-76, doi:10.1056/nejm199907083410202 (1999).

219. Bech, G. J. W. *et al.* Fractional Flow Reserve to Determine the Appropriateness of Angioplasty in Moderate Coronary Stenosis. *Circulation* **103**, 2928-2934, doi:doi:10.1161/01.CIR.103.24.2928 (2001).

220. Zimmermann, F. M. *et al.* Deferral vs. performance of percutaneous coronary intervention of functionally non-significant coronary stenosis: 15-year follow-up of the DEFER trial. *European Heart Journal* **36**, 3182-3188, doi:10.1093/eurheartj/ehv452 (2015).

221. Hueb, W. A. *et al.* The Medicine, Angioplasty or Surgery Study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses. *J Am Coll Cardiol* **26**, 1600-1605, doi:10.1016/0735-1097(95)00384-3 (1995).

222. Hueb, W. A. *et al.* Five-year follow-up of the medicine, angioplasty, or surgery study (MASS): A prospective, randomized trial of medical therapy, balloon angioplasty, or bypass surgery for single proximal left anterior descending coronary artery stenosis. *Circulation* **100**, Ii107-113, doi:10.1161/01.cir.100.suppl_2.ii-107 (1999).

223. Henderson, R. A. *et al.* Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. *J Am Coll Cardiol* **42**, 1161-1170, doi:10.1016/s0735-1097(03)00951-3 (2003).

224. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. *Lancet* **350**, 461-468 (1997).

225. Erne, P. *et al.* Effects of Percutaneous Coronary Interventions in Silent Ischemia After Myocardial InfarctionThe SWISSI II Randomized Controlled Trial. *JAMA* **297**, 1985-1991, doi:10.1001/jama.297.18.1985 (2007).

226. Pfisterer, M. Long-term outcome in elderly patients with chronic angina managed invasively versus by optimized medical therapy: four-year follow-up of the randomized Trial of Invasive versus Medical therapy in Elderly patients (TIME). *Circulation* **110**, 1213-1218, doi:10.1161/01.Cir.0000140983.69571.Ba (2004).
227. Hambrecht, R. *et al.* Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. *Circulation* **109**, 1371-1378, doi:10.1161/01.Cir.0000121360.31954.1f (2004).
228. Hueb, W. *et al.* Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. *Circulation* **115**, 1082-1089, doi:10.1161/circulationaha.106.625475 (2007).
229. Hueb, W. *et al.* The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. *J Am Coll Cardiol* **43**, 1743-1751, doi:10.1016/j.jacc.2003.08.065 (2004).
230. Frye, R. L. *et al.* A randomized trial of therapies for type 2 diabetes and coronary artery disease. *N Engl J Med* **360**, 2503-2515, doi:10.1056/NEJMoa0805796 (2009).
231. Boden, W. E. *et al.* Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med* **356**, 1503-1516, doi:10.1056/NEJMoa070829 (2007).
232. Xaplanteris, P. *et al.* Five-Year Outcomes with PCI Guided by Fractional Flow Reserve. *N Engl J Med* **379**, 250-259, doi:10.1056/NEJMoa1803538 (2018).
233. Maron, D. J. *et al.* Initial Invasive or Conservative Strategy for Stable Coronary Disease. *New England Journal of Medicine* **382**, 1395-1407, doi:10.1056/NEJMoa1915922 (2020).
234. Bangalore, S. *et al.* Management of Coronary Disease in Patients with Advanced Kidney Disease. *New England Journal of Medicine* **382**, 1608-1618, doi:10.1056/NEJMoa1915925 (2020).

235. Nishigaki, K. *et al.* Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study. *JACC Cardiovasc Interv* **1**, 469-479, doi:10.1016/j.jcin.2008.08.002 (2008).
236. Al-Lamee, R. *et al.* Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. *Lancet* **391**, 31-40, doi:10.1016/s0140-6736(17)32714-9 (2018).
237. Serruys, P. W. *et al.* A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease. *New England Journal of Medicine* **331**, 489-495, doi:10.1056/nejm199408253310801 (1994).
238. Macaya, C. *et al.* Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent trial. Benestent Study Group. *J Am Coll Cardiol* **27**, 255-261, doi:10.1016/0735-1097(95)00473-4 (1996).
239. Kiemeneij, F. *et al.* Continued benefit of coronary stenting versus balloon angioplasty: five-year clinical follow-up of Benestent-I trial. *J Am Coll Cardiol* **37**, 1598-1603, doi:10.1016/s0735-1097(01)01207-4 (2001).
240. Fischman, D. L. *et al.* A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease. *New England Journal of Medicine* **331**, 496-501, doi:10.1056/nejm199408253310802 (1994).
241. George, C. J. *et al.* One-year follow-up of the Stent Restenosis (STRESS I) Study. *Am J Cardiol* **81**, 860-865, doi:10.1016/s0002-9149(98)00004-6 (1998).
242. Kaiser, C. *et al.* Drug-Eluting versus Bare-Metal Stents in Large Coronary Arteries. *New England Journal of Medicine* **363**, 2310-2319, doi:10.1056/NEJMoa1009406 (2010).
243. von Birgelen, C. *et al.* Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-

eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial. *Lancet* **392**, 1235-1245, doi:10.1016/s0140-6736(18)32001-4 (2018).

244. Kandzari, D. E. *et al.* Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. *Lancet* **390**, 1843-1852, doi:10.1016/s0140-6736(17)32249-3 (2017).

245. Kandzari, D. E. *et al.* Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents. *J Am Coll Cardiol* **72**, 3287-3297, doi:10.1016/j.jacc.2018.09.019 (2018).

246. von Birgelen, C. *et al.* Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial. *The Lancet* **388**, 2607-2617, doi:https://doi.org/10.1016/S0140-6736(16)31920-1 (2016).

247. Pilgrim, T. *et al.* Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. *The Lancet* **384**, 2111-2122, doi:10.1016/S0140-6736(14)61038-2 (2014).

248. Pilgrim, T. *et al.* Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. *Lancet* **392**, 737-746, doi:10.1016/s0140-6736(18)31715-x (2018).

249. Kedhi, E. *et al.* Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. *Lancet* **375**, 201-209, doi:10.1016/s0140-6736(09)62127-9 (2010).

250. Smits, P. C. *et al.* 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial). *J Am Coll Cardiol* **58**, 11-18, doi:10.1016/j.jacc.2011.02.023 (2011).
251. Smits, P. C. *et al.* Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. *Lancet* **381**, 651-660, doi:10.1016/s0140-6736(12)61852-2 (2013).
252. Vlachojannis, G. J. *et al.* Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with coronary artery disease: three-year follow-up of the COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) trial. *EuroIntervention* **11**, 272-279, doi:10.4244/eijv11i3a53 (2015).
253. Davies, J. E. *et al.* Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. *New England Journal of Medicine* **376**, 1824-1834, doi:10.1056/NEJMoa1700445 (2017).
254. von Birgelen, C. *et al.* Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial. *Lancet* **383**, 413-423, doi:10.1016/s0140-6736(13)62037-1 (2014).
255. Sen, H. *et al.* Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II). *JACC Cardiovasc Interv* **8**, 889-899, doi:10.1016/j.jcin.2015.01.033 (2015).

256. Tonino, P. A. L. *et al.* Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention. *New England Journal of Medicine* **360**, 213-224, doi:10.1056/NEJMoa0807611 (2009).
257. van Nunen, L. X. *et al.* Fractional flow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease (FAME): 5-year follow-up of a randomised controlled trial. *Lancet* **386**, 1853-1860, doi:10.1016/s0140-6736(15)00057-4 (2015).
258. Götberg, M. *et al.* Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. *New England Journal of Medicine* **376**, 1813-1823, doi:10.1056/NEJMoa1616540 (2017).
259. Windecker, S. *et al.* Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. *Lancet* **372**, 1163-1173, doi:10.1016/s0140-6736(08)61244-1 (2008).
260. Urban, P. *et al.* Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. *New England Journal of Medicine* **373**, 2038-2047, doi:10.1056/NEJMoa1503943 (2015).
261. Nagel, E. *et al.* Magnetic Resonance Perfusion or Fractional Flow Reserve in Coronary Disease. *New England Journal of Medicine* **380**, 2418-2428, doi:10.1056/NEJMoa1716734 (2019).
262. Windecker, S. *et al.* Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. *New England Journal of Medicine* **382**, 1208-1218, doi:10.1056/NEJMoa1910021 (2020).
263. Morice, M. C. *et al.* A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. *N Engl J Med* **346**, 1773-1780,

doi:10.1056/NEJMoa012843 (2002).

264. Morice, M. C. *et al.* Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. *J Am Coll Cardiol* **50**, 1299-1304, doi:10.1016/j.jacc.2007.06.029 (2007).

265. Morice, M. C. *et al.* Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. *Jama* **295**, 895-904, doi:10.1001/jama.295.8.895 (2006).

266. Serruys, P. W. *et al.* Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. *N Engl J Med* **363**, 136-146, doi:10.1056/NEJMoa1004130 (2010).

267. Silber, S., Windecker, S., Vranckx, P. & Serruys, P. W. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. *Lancet* **377**, 1241-1247, doi:10.1016/s0140-6736(11)60395-4 (2011).

268. Varenne, O. *et al.* Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. *The Lancet* **391**, 41-50, doi:10.1016/S0140-6736(17)32713-7 (2018).

269. Windecker, S. *et al.* Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. *N Engl J Med* **353**, 653-662, doi:10.1056/NEJMoa051175 (2005).

270. Yamaji, K. *et al.* Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial. *European Heart Journal* **37**, 3386-3395, doi:10.1093/eurheartj/ehw343 (2016).

271. Moses, J. W. *et al.* Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. *N Engl J Med* **349**, 1315-1323, doi:10.1056/NEJMoa035071 (2003).

272. Weisz, G. *et al.* Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. *J Am Coll Cardiol* **53**, 1488-1497, doi:10.1016/j.jacc.2009.01.050 (2009).
273. Galløe, A. M. *et al.* Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. *Jama* **299**, 409-416, doi:10.1001/jama.299.4.409 (2008).
274. Rasmussen, K. *et al.* Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. *Lancet* **375**, 1090-1099, doi:10.1016/s0140-6736(10)60208-5 (2010).
275. Christiansen, E. H. *et al.* Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. *Lancet* **381**, 661-669, doi:10.1016/s0140-6736(12)61962-x (2013).
276. Stone, G. W. *et al.* Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. *Jama* **299**, 1903-1913, doi:10.1001/jama.299.16.1903 (2008).
277. Stone, G. W. *et al.* Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents. *Circulation* **119**, 680-686, doi:doi:10.1161/CIRCULATIONAHA.108.803528 (2009).
278. Stone, G. W. *et al.* Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. *N Engl J Med* **362**, 1663-1674, doi:10.1056/NEJMoa0910496 (2010).
279. Stone, G. W. *et al.* Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. *J Am Coll Cardiol* **58**, 19-25, doi:10.1016/j.jacc.2011.02.022 (2011).

280. Stone, G. W. *et al.* A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. *N Engl J Med* **350**, 221-231, doi:10.1056/NEJMoa032441 (2004).
281. Ellis, S. G. *et al.* Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). *JACC Cardiovasc Interv* **2**, 1248-1259, doi:10.1016/j.jcin.2009.10.003 (2009).
282. Stone, G. W. *et al.* Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. *Jama* **294**, 1215-1223, doi:10.1001/jama.294.10.1215 (2005).